سعر ايلاكسيكوبا 1 مجم 2022

Elaxicopa 1 mg film-coated tablets (doxazosin), 10 tablets, Copad Pharma, Egypt.

• Hypertension (alone or with other antihypertensives).Population: AdultsMHRA / eMC
• Benign prostatic hyperplasia — urinary outflow obstruction and BPH symptoms.Population: Adult menMHRA / eMC

• Common: dizziness, headache, somnolence, hypotension/postural hypotension, palpitation, tachycardia, respiratory symptoms, GI symptoms, back pain/myalgia, asthenia, peripheral oedema (see SmPC table).International label, equivalent formulation · MHRA / eMC

• Hypersensitivity to doxazosin/other quinazolines or excipients; history of orthostatic hypotension; BPH with upper urinary tract congestion, chronic UTI or bladder stones; hypotension (BPH indication); monotherapy in overflow bladder or anuria with/without progressive renal insufficiency.International label, equivalent formulation · MHRA / eMC

• Postural hypotension/syncope at initiation — monitor BP. Caution in acute cardiac conditions and hepatic impairment (not recommended in severe hepatic impairment). Caution with PDE-5 inhibitors. IFIS with alpha-1 blockers — inform cataract surgeon. Priapism — urgent care. Rule out prostate cancer before BPH treatment. Contains lactose.International label, equivalent formulation · MHRA / eMC

• PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)ModerateAdditive vasodilation may cause symptomatic hypotension; start PDE-5 only if hemodynamically stable on alpha-blocker; lowest dose; ≥6 h from doxazosin.MHRA / eMC
• Strong CYP3A4 inhibitorsDoxazosin is a CYP3A4 substrate; caution with strong inhibitors (e.g. clarithromycin, ketoconazole, ritonavir).MHRA / eMC

• No adequate well-controlled studies in pregnancy; use only if potential benefit outweighs risk. Animal studies: no teratogenicity seen; reduced fetal survival at extremely high doses.International label, equivalent formulation · MHRA / eMC
• Excretion in breast milk very low (relative infant dose <1%) but human data limited; risk to infant cannot be excluded — use only if benefit outweighs risk.International label, equivalent formulation · MHRA / eMC

• Doxazosin: Selectively blocks postsynaptic alpha-1 adrenoceptors in vascular and prostatic smooth muscle, reducing peripheral resistance and urethral tone.